BRPI0412457A - composição farmacêutica para aumento da solubilidade de drogas hidrofóbicas - Google Patents

composição farmacêutica para aumento da solubilidade de drogas hidrofóbicas

Info

Publication number
BRPI0412457A
BRPI0412457A BRPI0412457-0A BRPI0412457A BRPI0412457A BR PI0412457 A BRPI0412457 A BR PI0412457A BR PI0412457 A BRPI0412457 A BR PI0412457A BR PI0412457 A BRPI0412457 A BR PI0412457A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
solubility
increasing
polyethylene glycol
hydrophobic drugs
Prior art date
Application number
BRPI0412457-0A
Other languages
English (en)
Inventor
Anup Kumar Ray
Indranil Nandi
Suresh Palaniswamy
Pablo Dasvila
Aakanksha Harshad
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of BRPI0412457A publication Critical patent/BRPI0412457A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA PARA AUMENTO DA SOLUBILIDADE DE DROGAS HIDROFóBICAS". A presente invenção fornece uma composição farmacêutica contendo uma droga e polietileno glicol, na qual a razão em peso de polietileno glicol para a droga é de cerca de 0,2:1 a cerca de 10:1 e o polietileno glicol tem um ponto de fusão de pelo menos 37<198>C. As composições farmacêuticas da invenção exibem rápida dissolução em contato com solventes fisiológicos, tais como água, saliva ou fluidos gastrointestinais.
BRPI0412457-0A 2003-07-11 2004-07-09 composição farmacêutica para aumento da solubilidade de drogas hidrofóbicas BRPI0412457A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/618,545 US20050008704A1 (en) 2003-07-11 2003-07-11 Pharmaceutical composition for solubility enhancement of hydrophobic drugs
PCT/EP2004/007585 WO2005004917A2 (en) 2003-07-11 2004-07-09 Pharmaceutical composition for solubility enhancement of hydrophobic drugs

Publications (1)

Publication Number Publication Date
BRPI0412457A true BRPI0412457A (pt) 2006-10-17

Family

ID=33565153

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412457-0A BRPI0412457A (pt) 2003-07-11 2004-07-09 composição farmacêutica para aumento da solubilidade de drogas hidrofóbicas

Country Status (10)

Country Link
US (1) US20050008704A1 (pt)
EP (1) EP1646403A2 (pt)
CN (1) CN1856297A (pt)
AR (1) AR045906A1 (pt)
AU (1) AU2004255459A1 (pt)
BR (1) BRPI0412457A (pt)
CA (1) CA2529606A1 (pt)
MX (1) MXPA06000445A (pt)
RU (1) RU2006104025A (pt)
WO (1) WO2005004917A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572190B1 (en) * 2002-12-17 2007-04-18 Abbott GmbH & Co. KG Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
KR20060085686A (ko) * 2003-10-10 2006-07-27 라이프사이클 파마 에이/에스 피브레이트를 포함하는 고형 제제
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
EP1893182B8 (en) * 2005-05-26 2012-04-04 Teva Women's Health, Inc. Oral dosage forms comprising progesterone and method of making and using the same
JP2009543803A (ja) * 2006-07-12 2009-12-10 エラン・ファルマ・インターナショナル・リミテッド モダフィニルのナノ粒子製剤
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US7607596B1 (en) 2007-03-07 2009-10-27 Exxpharma, LLC Process for enhancing the solubility of poorly soluble drugs
US8173169B2 (en) 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
US20090155325A1 (en) * 2007-12-14 2009-06-18 Kimberly-Clark Worldwide, Inc. Formulation and products for promoting skin cleanliness and health
AT10562U3 (de) * 2008-12-05 2010-01-15 Aop Orphan Pharmaceuticals Ag Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie
DE102011010437A1 (de) * 2011-02-04 2012-08-09 J. Rettenmaier & Söhne Gmbh + Co. Kg Tablettierhilfsmittel
CN102321048A (zh) * 2011-06-13 2012-01-18 中国药科大学 糖精瑞格列奈无定形物
FR2987265B1 (fr) 2012-02-28 2014-02-28 Debregeas Et Associes Pharma Composition pharmaceutique sous forme de sirop a base de modafinil, son procede de fabrication et son application
WO2014045307A2 (en) 2012-09-20 2014-03-27 Ipca Laboratories Limited Pharmaceutical composition
CN103006570B (zh) * 2012-10-08 2013-12-25 孙维会 一种阿佐昔芬速释微丸及其制备方法
DK2915526T3 (da) * 2014-03-07 2021-09-06 Galenicum Health S L U Farmaceutiske sammensætninger, der omfatter anagrelid
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
WO2016198166A1 (en) * 2015-06-10 2016-12-15 Disphar International B.V. Improved pharmaceutical formulation
EP3108879A1 (en) 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
EP3576718B1 (en) * 2017-02-01 2021-07-14 Johnson & Johnson Consumer Inc. A lozenge
TWI661841B (zh) * 2017-04-19 2019-06-11 三凡生技研發股份有限公司 用於分散疏水性植物萃取物之載劑
EP3586827A1 (en) 2018-06-29 2020-01-01 Consejo Superior de Investigaciones Cientificas (CSIC) Pharmaceutical formulation with improved solubility and bioavailability
CA3188796A1 (en) * 2020-07-07 2022-01-13 Atxa Therapeutics Limited Thromboxane receptor antagonist formulations
CN114306253B (zh) * 2021-11-16 2023-08-22 扬子江药业集团广州海瑞药业有限公司 格列美脲片剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811120A (en) * 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
IL112746A (en) * 1994-03-02 1999-12-31 Lilly Co Eli Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride
JP2002514174A (ja) * 1996-08-28 2002-05-14 イーライ・リリー・アンド・カンパニー 非晶質ベンゾチオフェン類、製造方法および使用方法
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds

Also Published As

Publication number Publication date
US20050008704A1 (en) 2005-01-13
WO2005004917A3 (en) 2006-03-16
EP1646403A2 (en) 2006-04-19
WO2005004917A2 (en) 2005-01-20
MXPA06000445A (es) 2006-04-05
CA2529606A1 (en) 2005-01-20
AU2004255459A1 (en) 2005-01-20
AR045906A1 (es) 2005-11-16
RU2006104025A (ru) 2007-08-27
CN1856297A (zh) 2006-11-01

Similar Documents

Publication Publication Date Title
WO2005004917A3 (en) Pharmaceutical composition for solubility enhancement of hydrophobic drugs
BR0206580A (pt) Composição farmacêutica tendo tendência reduzida para cristalização de droga
BRPI0511966A (pt) composições farmacêuticas contendo polietileno glicol tendo um peso molecular menor do que 600 daltons
BR9907647A (pt) Composições contendo composto orgânicos
MXPA05010859A (es) Antagonistas mchr1 heterociclicos.
SE0102764D0 (sv) Compounds
BRPI0414000B8 (pt) composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
CY1114521T1 (el) Ενωσεις βενζαμιδιου χρησιμες ως αναστολεις αποακετυλασων ιστονων
WO2005072343A3 (en) Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use
BR0209489A (pt) Composições farmacêuticas
BRPI0408251A (pt) compostos de pirazina como inibidores do fator de crescimento transformante (tgf)
BRPI0619153A8 (pt) derivados de 4-aminopirroltriazina substituída, e composição farmacêutica
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
PA8583301A1 (es) Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
BRPI0714055B8 (pt) compostos moduladores de propriedades farmacocinéticas de terapêuticos, composições farmacêuticas que compreendem os referidos compostos e usos dos mesmo
UY27983A1 (es) Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf)
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
BRPI0406715A (pt) Inibidores seletivos de ciclooxigenase-2 antiinflamatórios
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
MA30410B1 (fr) Dimeres de derives d&#39;artemisinine, leur preparation et leur application en therapeutique.
BR0313428A (pt) Composições farmacêuticas de drogas semi-ordenados e polìmeros
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
EA200600694A1 (ru) Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BR0312033A (pt) Formulações para depósito de curta duração

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired